Efficacy of ursodeoxycholic acid in treatment of early diabetic nephropathy: report of 40 cases

Jiawei YU; Bing FENG; Wei ZENG; Yi WEI; Limin WANG

doi:10.16016/j.1000-5404.201803038

您当前的位置：

首页 >

文章列表页 >

Efficacy of ursodeoxycholic acid in treatment of early diabetic nephropathy: report of 40 cases

Clinical Medicine | 更新时间：2026-01-09

- Efficacy of ursodeoxycholic acid in treatment of early diabetic nephropathy: report of 40 cases
- Journal of Third Military Medical University Vol. 40, Issue 20, Pages: 1870-1875(2018)
- 作者机构：
  
  1.400037 重庆，陆军军医大学(第三军医大学)第二附属医院肾内科
  2.450042 郑州，河南省人民医院内分泌科
- 作者简介：
- 基金信息：
- DOI：10.16016/j.1000-5404.201803038
  CLC： R587.1;R692.39;R975.5
- Received：06 March 2018，
  
  Revised：2018-05-15，
  
  Published：30 October 2018
- 稿件说明：
移动端阅览
Jiawei YU, Bing FENG, Wei ZENG, et al. Efficacy of ursodeoxycholic acid in treatment of early diabetic nephropathy: report of 40 cases[J]. Journal of Third Military Medical University, 2018, 40(20): 1870-1875.
DOI：

Jiawei YU, Bing FENG, Wei ZENG, et al. Efficacy of ursodeoxycholic acid in treatment of early diabetic nephropathy: report of 40 cases[J]. Journal of Third Military Medical University, 2018, 40(20): 1870-1875. DOI： 10.16016/j.1000-5404.201803038.

摘要

目的

观察熊去氧胆酸(ursodeoxycholic acid，UDCA)对糖尿病肾病(diabetic nephropathy，DN)Ⅲ期患者的疗效。

方法

选择2016年5-12月在陆军军医大学第二附属医院肾内科诊断明确的DNⅢ期微量白蛋白尿期(Mogensen分期Ⅲ期)患者40例，年龄30~59岁，糖尿病病程6个月至30年，采用计算机随机分组方法将患者等分为2组：①厄贝沙坦组，患者口服厄贝沙坦片，0.15 g/d；②UDCA组，患者饭后口服UDCA胶囊，250 mg/d。治疗周期12个月。主要观察指标包括尿蛋白/肌酐值、血肌酐、肾小球滤过率(eGFR)，以及血液炎症细胞因子表达变化。

结果

至治疗期结束，厄贝沙坦组蛋白肌酐比值下降14.94%，血肌酐下降7.73%，eGFR增加8.64%，与治疗前比较，差异均有统计学意义(

0.05)；UDCA组蛋白/肌酐值下降10.39%，血肌酐下降6.49%，eGFR治疗前后增加7.41%，与治疗前比较，差异均有统计学意义(

0.05)。两组间比较，各观察指标的差异无统计学意义(

0.05)。与治疗前比较，厄贝沙坦组患者血浆中CRP、IL-6、TNF-α含量分别降低13.7%、8.7%、5.9%，差异均有统计学意义(

0.05)；与治疗前比较，UDCA组血浆中CRP、IL-6、TNF-α含量分别降低16.2%、14.1%、16.8%，差异均有统计学意义(

0.05)。两组间比较，血浆中各个炎症细胞因子含量变化的差异无统计学意义(

0.05)。

结论

UDCA可以显著降低DN Ⅲ期患者的尿蛋白/肌酐值，保护肾功能，与厄贝沙坦疗效相当。

Abstract

Objective

To observe the therapeutic effect of ursodeoxycholic acid (UDCA) for patients with early diabetic nephropathy (DN).

Methods

From May 2016 to December 2016

a total of 40 patients with early DN (Mogensen stage Ⅲ) were diagnosed in the Nephrology Department of Xinqiao Hospital

aged 30 to 59 years

with the course of disease ranging from 6 months to 30 years

were randomized equally into aprovel group (0.15 g/d) and UDCA group (250 mg/d after meal). The levels of urinary microalbumin

urinary albumin/creatinine ratio

creatinine

and estimated glomerular filtration rate (eGFR)

and the contents of inflammatory cytokines in blood and urine were measured or calculated before and in 12 months after treatment

and the results were compared between the 2 groups.

Results

After 12 months of treatment

the patients in the aprovel group had the urinary albumin/creatinine ratio reduced by 14.94% and creatinine level by 7.73%

while eGFR increased by 8.64%

and significant differences were noted when compared with the values before treatment (

0.05). Similar changes were also observed in the UDCA group (10.39%

6.49% and 7.41%

respectively

0.05). But there were no significant differences in above indicators between the 2 groups (

0.05). Aprovel treatment significantly decreased the serum levels of CRP

IL-6 and TNF-α by 13.7%

8.7% and 5.9%

respectively

and UDCA also obviously reduced the levels by 16.2%

14.1% and 16.8%

respectively. But no significant differences were observed between the 2 groups (

0.05).

Conclusions

UDCA could decrease the urinary albumin/creatinine ratio

protect renal function and exert similar effects in the patients with stage Ⅲ.

关键词

Keywords

references

杨刚, 范秋灵, 刘晓丹, 等.蛋白质组学及其在糖尿病肾病中的应用[J].实用医学杂志, 2011, 27(10): 1892-1893.

YANG G, FAN Q L, LIU X D, et al. Proteomics and its application in diabetic nephropathy[J]. J Pract Med, 2011, 27(10): 1892-1893.

GRAY S P, COOPER M E. Diabetic nephropathy in 2010: Alleviating the burden of diabetic nephropathy[J]. Nat Rev Nephrol, 2011, 7(2): 71-73. DOI:10.1038/nrneph.2010.176.

XU Y, WANG L, HE J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310(9): 948-959. DOI:10.1001/jama.2013.168118.

SONG M K, DAVIES N M, ROUFOGALIS B D, et al. Management of cardiorenal metabolic syndrome in diabetes mellitus: a phytotherapeutic perspective[J]. J Diabetes Res, 2014, 2014:313718. DOI:10.1155/2014/313718.

ROSCIONI S S, HEERSPINK H J, DEZEEUW D. The effect of RAAS blockade on the progression of diabetic nephropathy[J]. Nat Rev Nephrol, 2014, 10(2):77-87. DOI:10.1038/nrneph.2013.251.

陈吉刚, 庞琦, 曾薇, 等.甜菜碱对糖尿病肾病小鼠的治疗作用及其机制[J].第三军医大学学报, 2012, 34(11): 1040-1043.

CHEN J G, PANG Q, ZEGN W, et al. Therapeutic effect of betaine on diabetic nephropathy in db/db mice[J]. J Third Mil Med Univ, 2012, 34(11):1040-1043.

LIU J, YANG J R, CHEN X M, et al. Impact of ER stress-regulated ATF4/p16 signaling on the premature senescence of renal tubular epithelial cells in diabetic nephropathy[J]. Am J Physiol Cell Physiol, 2015, 308(8): C621-C630. DOI:10.1152/ajpcell.00096.2014.

LI J, WANG J J, ZHANG S X. Preconditioning with endoplasmic reticulum stress mitigates retinal endothelial inflammation via activation of x-box binding protein 1[J]. J Biol Chem, 2010, 286(6):4912-4921. DOI:10.1074/jbc.m110.199729.

GAO X, FU L, XIAOM, et al. The nephroprotective effect of tauroursodeoxycholic acid on ischaemia/reperfusion-induced acute kidney injury by inhibiting endoplasmic reticulum stress[J]. Basic Clin Pharmacol Toxicol, 2012, 111(1): 14-23. DOI:10.1111/j.1742-7843.2011.00854.x.

TANG C H, RANATUNGA S, KRISS C L, et al. Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival[J]. J Clin Invest, 2014, 124(6): 2585-2598. DOI:10.1172/JCI73448.

吴丽婷, 刘梦琼.胱抑素C联合eGFR-MDRD诊断早期DN的研究[J].中国免疫学杂志, 2015, 31(10):1394- 1396, 1399. DOI:10.3969/j.issn.1000-484X.2015.10.021.

WU L T, LIU M Q. Studies of cystatin C joint eGFR-MDRD for diagnosis of early DN[J]. Chin J Immunol, 2015, 31(10):1394-1396, 1399.DOI:10.3969/j.issn.1000-484X.2015.10.021.

PALMER S C, MAVRIDIS D, NAVARESE E, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis[J]. Lancet, 2015, 385(9982):2047-2056. DOI:10.1016/S0140-6736(14)62459-4.

HOTAMISLIGIL G S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease[J]. Cell, 2010, 140(6): 900-917. DOI:10.1016/j.cell.2010.02.034.

CUNARD R. Endoplasmic reticulum stress in the diabetic kidney, the good, the bad and the ugly[J]. J Clin Med, 2015, 4(4): 715-740. DOI:10.3390/jcm4040715.

DELEPINE M, NICOLINO M, BARRETT T, et al. EIF2AK3, encoding translation initiation factor 2-α kinase 3, is mutated in patients with Wolcott-Rallison syndrome[J]. Nat Genet, 2000, 25(4):406-409. DOI: 10.1038/78085.

MADHUSUDHAN T, WANG H, DONG W, et al.Defective podocyte insulin signalling through p85-XBP1 promotes ATF6-dependent maladaptive ER-stress response in diabetic nephropathy[J]. Nat Commun, 2015, 6: 6496. DOI: 10.1038/ncomms7496.

RUILOPE L M, MALACCO E, KHDER Y, et al.Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors:The VAST study[J]. Clin Ther, 2005, 27(5): 578-588. DOI:10.1016/j.clinthera.2005.05.006.

黄欣, 许冬梅.肾病药物治疗学[M].北京:化学工业出版社, 2010:209-210.

HUANG X, XU D M. Nephrotictherapy[M]. Beijing: Chemical Industry Press, 2010:209-210.

吴泽成, 刘慎微.缬沙坦对2型糖尿病模型大鼠肾组织巨噬细胞浸润的影响[J].医药导报, 2008, 27(3): 268-271.

WU Z C, LIU S W. Effect of valsartan on macrophage infiltration in renal tissue of type 2 diabetic rats[J]. Herald Med, 2008, 27(3): 268-271.

CAO A, WANG L, CHEN X, et al. Ursodeoxycholicacid ameliorated diabetic nephropathy by attenuating hyperglycemia-mediated oxidative stress[J]. Biol Pharm Bull, 2016, 39(8): 1300-1308. DOI:10.1248/bpb.b16-00094.

VANG S, LONGLEY K, STEER C J, et al. The unexpected uses of urso-and tauroursodeoxycholicacid in the treatment of non-liver diseases[J]. Glob Adv Health Med, 2014, 3(3): 58-69. DOI:10.7453/gahmj.2014.017.

MIN J H, HONG Y H, SUNG J J, et al. Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trial[J]. J Korean Med Sci, 2012, 27(2): 200-206. DOI:10.3346/jkms.2012.27.2.200.

PARVING H H, CHATURVEDI N, VIBERTI G, et al. Does microalbuminuria predict diabetic nephropathy[J]. Diabetes Care, 2002, 25(2): 406-407. DOI:10.2337/diacare.25.2.406.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Screening and validation of key molecular targets for dihydromyricetin in ameliorating diabetic nephropathy

Mitochondrial dynamics in the pathogenesis of diabetic complications

Low-dose LPS promotes progress of non-alcoholic steatohepatitis by up-regulating TLR4 in macrophages

Effect and mechanism of human umbilical cord mesenchymal stem cells on preventing murine acute graft-versus-host disease

Effect of modulating thrombomodulin expression on renal injury in rats with diabetic nephropathy

Related Author

LIU Xingran

NIU Mengzhu

GAO Yuan

CHEN Dandan

ZHANG Baowen

LIU Dekun

LIU Xiaoqian

KOU Xianjuan

Related Institution

College of Sports Medicine， Wuhan Sports University

College of Physical Education and Health， Guangxi Medical University

School of Sports Science and Health， Harbin Sport University

School of Physical Education， Guangxi University of Science and Technology

Hubei Key Laboratory of Sport Training and Monitoring

⁰